Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Journal of Cancer Research and Clinical Oncology|June 24, 2022
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patientsAndrea De Giglio, Chiara Deiana, Alessandro Di Federico
European Journal of Cancer (Oxford, England : 1990)|September 9, 2021
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?Alessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
Med (New York, N.Y.)|January 13, 2024
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapyAndrea De Giglio, Alessandro Di Federico, Eleonora Gariazzo, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2021
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER databaseAndrea De Giglio, Alessandro Di Federico, Francesco Gelsomino, et al.
Future Oncology (London, England)|June 17, 2020
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implicationGiuseppe Lamberti, Elisa Andrini, Monia Sisi, et al.
Current Oncology Reports|August 28, 2021
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)Andrea De Giglio, Alessandro Di Federico, Giacomo Nuvola, et al.
Critical Reviews in Oncology/Hematology|March 23, 2021
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategyAlessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
Expert Review of Gastroenterology & Hepatology|March 31, 2021
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issueAlessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, et al.
Anti-Cancer Drugs|August 23, 2020
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?Alessandro Di Federico, Giacomo Nuvola, Monia Sisi, et al.
Biomolecules|December 23, 2023
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and BeyondMirta Mosca, Maria Concetta Nigro, Rachele Pagani, et al.
Pageof 11